BIOLASE, Inc. (Nasdaq: BIOL) (“Biolase” or the “Company”) is a leading provider of advanced laser systems for the dental industry. The Company develops, manufactures, markets, and sells laser systems that provide significant benefits for dental practitioners and their patients. The Company's proprietary systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. Its laser systems are designed to provide clinically superior results for many types of dental procedures compared to those achieved with drills, scalpels, and other conventional instruments. Potential patient benefits include less pain, fewer shots, faster healing, decreased fear and anxiety, and fewer appointments. Potential practitioner benefits include improved patient care and the ability to perform higher volume and wider variety of procedures and generate more patient referrals. The Company offers two categories of laser system products: Waterlase (all-tissue) systems and diode (soft-tissue) systems.
The Company also manufactures and sells consumable products and accessories for their laser systems. The Waterlase and diode systems use disposable laser tips of differing sizes and shapes depending on the procedure being performed. The Company also markets flexible fibers and hand pieces that dental practitioners replace after initially purchasing laser systems.
Epic Hygiene is the Company’s latest innovation in proven Epic laser technology, which is designed to manage non-surgical periodontitis and increase clinical production. The system includes proven step-by-step clinical protocols, including pocket therapy and perio debridement, for implementation. Epic Hygiene now gives dental hygienists the ability to offer dental laser technology to their patients, including minimally invasive and less painful treatments that are designed to allow for quicker procedures and faster recovery times. Each system includes hygiene specific training, turnkey practice guidebooks with step-by-step practice integration tips, as well as access to exclusive on-call Epic expert support, with clinicians to provide peer to peer support.
Biolase has a complete line of products for both general dentists, specialists and
dental practitioners. Their flagship brand, the Waterlase, uses a patented
combination of water and laser energy and is FDA cleared for over 80 clinical
indications to perform most procedures currently performed using drills, scalpels,
and other traditional dental instruments for cutting soft and hard tissue. For example,
Waterlase safely debrides implants without damaging or significantly affecting
surface temperature and is an effective, safe solution for preserving sick implants. In pain therapy, and cosmetic procedures, including teeth whitening.
Dental procedures, including medical and cosmetic treatment, are performed on hard tissue, such as bone and teeth, and soft tissue, such as gum and other oral tissue.
An estimated one-third of the worldwide population avoids going to the dentist because of “dental anxiety or fear,” according to DentaVox.1 Due to the limitations associated with traditional and alternative dental instruments, Biolase believes there is a large market opportunity for all-tissue dental laser systems. The Company also believes there is a growing awareness among consumers globally of the value and importance of oral health and its connections to overall systemic health and wellness. The American Academy of Periodontology estimates that over 60 million people in the U.S. alone have periodontitis, and studies indicate a link between periodontitis and other health conditions such as heart disease, diabetes, and stroke.2
As of 2018, according to the American Dental Association, there were 199,486 active private dental practitioners in the U.S.3 An April 2019 study published by Grandview Research estimated the global dental equipment market to be $7.7 billion in 2018 and projected it to grow at a compound annual rate of 4.5% through 2025.4 The study also highlighted that dental laser equipment is expected to be the fastest growing segment with compound annual growth of 6.8% over the forecast period. Biolase believes that all-tissue laser systems have penetrated only 7% of U.S. dental practices and 1.4% worldwide.
(1) https://www.dentalproductsreport.com/view/study-finds-more-60-percent-people-suffer-dental-fear
(2) https://www.perio.org/consumer/cdc-study.htm
(3) https://www.ada.org/~/media/ADA/Science%20and%20Research/HPI/Files/HPIdata_SOD_2018.xlsx?la=en
(4) https://www.grandviewresearch.com/press-release/global-dental-equipment-market
This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.
BIOLASE, Inc (the “Company”) and its counsel have reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.
Information and opinions presented in the Company Presentation are provided by the Company, and b2i Digital makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment.
Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.
A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.
Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.
b2i Digital or its related entities may own securities of the Company.
To comply with Rule 17(b) of the Securities Act of 1933, as amended, b2i Digital must provide full disclosure of all compensation received for investor awareness services provided by the Company.
The Company is a client of b2i Digital. The Company agreed to pay b2i Digital no greater than $72,000 in cash for 12 months of digital marketing consulting and investor awareness services.
b2i Digital has received compensation from the Company in the past 12 months in connection with investment banking services pursuant to a separate agreement and may receive compensation for future services.